Related Experiment Video
Updated: Aug 5, 2026
07:31
A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
Published on: February 13, 2020
Does concurrent pharmacotherapy enhance behavioral interventions for mild cognitive impairment? Evidence from the
Zhigang Xie1, Dona Locke2, Anni Shandera-Ochsner3
1Department of Health Services Research, Management and Policy, University of Florida, Gainesville, FL, USA.
Journal of Alzheimer'S Disease : JAD
|July 27, 2026
Summary
Combining pharmacotherapy with behavioral interventions did not enhance outcomes for individuals with mild cognitive impairment (MCI). Pharmacotherapy users showed similar benefits but also faster decline in daily functioning compared to those only using behavioral interventions.
Area of Science:
- Neurology
- Gerontology
- Behavioral Science
Background:
- Mild cognitive impairment (MCI) is a critical stage for interventions to slow cognitive decline.
- Both pharmacotherapy and behavioral interventions are used to manage MCI.
- Combining treatments may offer synergistic benefits.
Purpose of the Study:
- To determine if combining pharmacotherapy with multicomponent behavioral interventions improves outcomes for people with MCI (pwMCI) compared to behavioral interventions alone.
- To evaluate the impact on functional skills, quality of life, and adherence.
Main Methods:
- 1074 pwMCI in the HABIT program were analyzed.
- Participants were grouped based on baseline pharmacotherapy use (acetylcholinesterase inhibitors and/or glutamate regulators).
- Multivariate linear mixed-effects models assessed changes in outcomes over 12 months, adjusting for baseline severity.
Main Results:
- Pharmacotherapy users (38.5%) had more severe baseline cognitive impairment and lower rehabilitation use.
- Both groups improved post-intervention, with pharmacotherapy users showing higher HABIT compliance.
- By 12 months, pharmacotherapy users experienced greater decline in memory and executive function skills.
Conclusions:
- pwMCI on pharmacotherapy had more advanced MCI at study entry.
- Pharmacotherapy did not enhance intervention benefits or slow long-term cognitive decline.
- The combination did not yield superior outcomes compared to behavioral interventions alone.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:24Operant Conditioning Intervention
Operant conditioning serves as a foundational principle in therapeutic interventions aimed at modifying maladaptive behaviors. Central to this approach is the notion that behaviors, both adaptive and maladaptive, are learned through reinforcement. By analyzing the environmental factors that reinforce problematic behaviors, clinicians can design interventions to weaken these reinforcements and replace maladaptive behaviors with healthier alternatives.
In operant conditioning, behaviors that are...
In operant conditioning, behaviors that are...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:15Drug Abuse and Addiction: Pharmacological Phenomena
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...